 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| LY 3475070 / Eli Lilly
Trial completion, Enrollment change, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - Nov 28, 2022
P1, N=52, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | N=150 --> 52
- | LY 3475070 / Eli Lilly
Trial completion date, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 10, 2022
P1, N=150, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | N=150 --> 52 Trial completion date: Dec 2021 --> Jun 2022
- || LY 3475070 / Eli Lilly
Enrollment closed, Trial completion date, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - May 19, 2021
P1, N=150, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2021 --> Jun 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2021
- ||| LY 3475070 / Eli Lilly
Enrollment open, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - May 18, 2020
P1, N=120, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2021 Suspended --> Recruiting
- |||| LY 3475070 / Eli Lilly
Trial suspension, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 21, 2020
P1, N=120, Suspended, Sponsor: Eli Lilly and Company
Suspended --> Recruiting Recruiting --> Suspended
- ||| LY 3475070 / Eli Lilly
Enrollment open, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - Jan 8, 2020
P1, N=120, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Suspended Not yet recruiting --> Recruiting
- ||| LY 3475070 / Eli Lilly
New P1 trial, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - Nov 4, 2019
P1, N=120, Not yet recruiting, Sponsor: Eli Lilly and Company